Expert Case Series: The Burden of AD in Pediatric Patients
Dermatology
Discover clinical insights with Prof. Jonathan Silverberg: Uncovering the multidimensional burden of atopic dermatitis via this interactive case study.
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – PatientCase Follow-Up
Pulmonology
In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier revisits a patientcase study where a biologic has been added to an asthma management plan and describes the potential for this patient to achieve on-therapy clinical remission.
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – PatientCase Introduction
Pulmonology
In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier describes a typical patient presentation in the pediatric asthma clinic and explores whether clinical remission is a goal of treatment for this patient and others like them.
Learn about the guidelines for diagnosis, treatment options, and criteria for treatment response in EoE through the journey of a hypothetical EoE patient
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.